Successful treatment of PD-1 inhibitor-induced psoriasis with infliximab

J Eur Acad Dermatol Venereol. 2023 May;37(5):e621-e623. doi: 10.1111/jdv.18780. Epub 2022 Nov 30.

Authors

Inga Hansen¹, Isabel Heidrich¹, Finn Abeck¹, Julian Kött¹, Nina Booken¹, Christoffer Gebhardt¹, Stefan W Schneider¹

Affiliation

¹ Department of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

PMID: 36424911
DOI: 10.1111/jdv.18780

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / adverse effects
Dermatologic Agents* / adverse effects
Humans
Immune Checkpoint Inhibitors / adverse effects
Infliximab / adverse effects
Psoriasis* / chemically induced
Psoriasis* / drug therapy
Treatment Outcome
Tumor Necrosis Factor-alpha

Substances

Infliximab
Immune Checkpoint Inhibitors
Antibodies, Monoclonal
Dermatologic Agents
Tumor Necrosis Factor-alpha